New Drug Pricing and Market Access

In this episode of our life science industry podcast, Dr. Peter Bak sits down with Brendan Wang and Christian Thienel of Back Bay Life Science Advisors to discuss how pharmaceutical companies price their drugs.  They cover the ins and outs of health economics, how payers make sense of a high price, and ways this varies around the globe. With a focus on Biogen’s recent Aduhelm approval, the discussion includes how Biogen likely went about price setting and how this aligns with ICER’s initial evaluation and analysis.Topics in this podcast include:Relevant pricing analogsNet level pricing decisionsDemand and utilization of products affecting pricingPatient population levelsICER’s role in drug pricingThe price point of a drug, given its controversial approvalRead Back Bay’s perspective on early-stage market access and price setting in STAT News, here.Make sure to subscribe to The Life Science Report podcast and follow Back Bay Life Science Advisors on LinkedIn and Twitter. Thank you for joining us.